Viatris INC Schedule 13G passive stakes

Davis Selected Advisers has updated its Schedule 13G filing, reporting beneficial ownership of 75,232,254 shares, representing 6.5% of Viatris Inc.'s common stock.

Davis Selected Advisers has reported a beneficial ownership of 78,211,191 shares of Viatris Inc. common stock, representing 6.8% of the class, as of March 31, 2026.

Vanguard Capital Management disclosed a beneficial ownership of 7.36% of Viatris Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in Viatris Inc. following an internal corporate realignment.

Investment adviser Davis Selected Advisers has increased its beneficial ownership in Viatris Inc. to 6.1% of common stock.

Davis Selected Advisers reported an increased beneficial ownership of Viatris Inc. common stock, now holding 6.7% of the class.

BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting beneficial ownership of 6.6% of Viatris Inc.'s common stock as of September 30, 2025.

State Street Corporation has filed a Schedule 13G, reporting a 4.7% beneficial ownership stake in Viatris Inc. common stock.

Davis Selected Advisers has reported a 6.2% beneficial ownership stake in Viatris Inc. common stock.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, revealing a significant beneficial ownership of 6.3% in Viatris Inc.'s common stock as of March 31, 2025.

Investment adviser Davis Selected Advisers has reported a 6.0% beneficial ownership stake in pharmaceutical company Viatris Inc., holding over 64 million shares.

Davis Selected Advisers has disclosed a 5.9% ownership stake in Viatris Inc. as of December 31, 2024.